Rapid Rx Quiz: Myasthenia Gravis Treatments

Mary L. Windle, PharmD


March 15, 2022

Efgartigimod is FDA-approved and indicated for treating generalized MG in adults who test positive for antiacetylcholine receptor (AChR) antibodies. In phase 3 trials, treatment with efgartigimod reduced disease burden and improved strength and quality of life in patients with generalized MG across four MG-specific scales. These benefits were observed early and were reproducible and durable.

Efgartigimod is an antibody fragment designed to block the immunoglobulin (Ig) G recycling process and reduce pathogenic IgG antibodies, which most patients with  generalized MG have. The agent reduces IgG antibody levels by binding to and blocking the neonatal Fc receptor.

Learn more about efgartigimod.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.